Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tafluprost + dorzolamide + timolol
- Development stage
- Preclinical
- Lead developer
- Santen Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Administration
- Ophthalmic
01
Overview
This is a fixed-dose combination ophthalmic drug containing three active ingredients—tafluprost, dorzolamide, and timolol. Tafluprost is a prostaglandin F2α analog that increases the outflow of aqueous humor from the eye, thereby reducing intraocular pressure (IOP). Dorzolamide is a topical carbonic anhydrase inhibitor that decreases aqueous humor production. Timolol is a non-selective beta-adrenergic antagonist (beta blocker) that also reduces aqueous humor production. The combination targets multiple pathways to lower IOP and is intended for use in patients with open-angle glaucoma or ocular hypertension who require additional IOP reduction beyond monotherapy or dual therapy[1][2][5]. This triple-combination approach may offer enhanced efficacy for patients insufficiently controlled on fewer agents.
- Other names
- tafluprost + dorzolamide + timolol
02
Targets
ADRB1 (β1)CA2 (Carbonic Anhydrase 2)PTGFR (Prostaglandin F2 alpha receptor)ADRB2 (β2)
Beyond the preview
Go deeper on tafluprost + dorzolamide + timolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tafluprost + dorzolamide + timolol.